Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors

Neuropharmacology

Volumn 87, Issue , 2014, Pages 214-221

  Nader, Joëlle ^a,b   Rapino, Cinzia ^c   Gennequin, Benjamin ^a,b,i   Chavant, Francois ^b,d   Francheteau, Maureen ^a,b   Makriyannis, Alexandros ^e   Duranti, Andrea ^f   Maccarrone, Mauro ^g,h   Solinas, Marcello ^a,b   Thiriet, Nathalie ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c UNIVERSITY OF TERAMO   (Italy)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e NORTHEASTERN UNIVERSITY   (United States)

^f UNIVERSITY OF URBINO   (Italy)

^g UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^h IRCCS FONDAZIONE SANTA LUCIA   (Italy)

ⁱ UNIVERSITY OF BONN   (Germany)

Author keywords

Endocannabinoids; Methamphetamine; Neuroinflammation; Neuroprotection; Neurotoxicity; THC

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ESTERASE INHIBITOR; JZL 184; METHAMPHETAMINE; PLACEBO; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 2-ARACHIDONYLGLYCEROL; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; ACYLGLYCEROL; AMIDE; ARACHIDONIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; CANNABINOID RECEPTOR AFFECTING AGENT; CARBAMIC ACID DERIVATIVE; CENTRAL STIMULANT AGENT; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; ENDOCANNABINOID; ENZYME INHIBITOR; PIPERIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; BRAIN REGION; CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRADATION KINETICS; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENDOCANNABINOID SYSTEM; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; METHAMPHETAMINE DEPENDENCE; MOUSE; MOUSE MODEL; NERVOUS SYSTEM; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN INTERACTION; RECEPTOR UPREGULATION; RISK REDUCTION; TOXICOKINETICS; UPREGULATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; METABOLISM; NEOSTRIATUM; NEUROTOXICITY SYNDROMES; RANDOMIZATION;

ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; BENZODIOXOLES; CANNABINOID RECEPTOR MODULATORS; CARBAMATES; CENTRAL NERVOUS SYSTEM STIMULANTS; DRONABINOL; ENDOCANNABINOIDS; ENZYME INHIBITORS; GLYCERIDES; MALE; METHAMPHETAMINE; MICE, INBRED C57BL; NEOSTRIATUM; NEUROTOXICITY SYNDROMES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; RANDOM ALLOCATION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE 3-MONOOXYGENASE;

EID: 84908498195     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.03.014     Document Type: Article

References (78)

1. J. Bergman, M.S. Delatte, C.A. Paronis, K. Vemuri, G.A. Thakur, and A. Makriyannis Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties Physiol. Behav. 93 2008 666 670
2. T. Bisogno, and M. Maccarrone Latest advances in the discovery of fatty acid amide hydrolase inhibitors Expert Opin. Drug. Discov. 8 2013 509 522
3. J.F. Bowyer, B. Robinson, S. Ali, and L.C. Schmued Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure Synapse 62 2008 193 204
4. G.A. Cabral, E.S. Raborn, L. Griffin, J. Dennis, and F. Marciano-Cabral CB2 receptors in the brain: role in central immune function Br. J. Pharmacol. 153 2008 240 251
5. J.L. Cadet, S. Jayanthi, and X. Deng Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis FASEB J. 17 2003 1775 1788
6. C. Davidson, A.J. Gow, T.H. Lee, and E.H. Ellinwood Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment Brain Res. Brain Res. Rev. 36 2001 1 22
7. M. Degn, K.L. Lambertsen, G. Petersen, M. Meldgaard, A. Artmann, B.H. Clausen, S.H. Hansen, B. Finsen, H.S. Hansen, and T.M. Lund Changes in brain levels of N-acylethanolamines and 2-arachidonoylglycerol in focal cerebral ischemia in mice J. Neurochem. 103 2007 1907 1916
8. W.A. Devane, A. Breuer, T. Sheskin, T.U. JÃCurrency signrbe, M.S. Eisen, and R. Mechoulam A novel probe for the cannabinoid receptor J. Med. Chem. 35 1992 2065 2069
9. V. Di Marzo, M. Bifulco, and L. De Petrocellis The endocannabinoid system and its therapeutic exploitation Nat. Rev. Drug. Discov. 3 2004 771 784
10. T.P. Dinh, D. Carpenter, F.M. Leslie, T.F. Freund, I. Katona, S.L. Sensi, S. Kathuria, and D. Piomelli Brain monoglyceride lipase participating in endocannabinoid inactivation Proc. Natl. Acad. Sci. U. S. A. 99 2002 10819 10824
11. J. Fernandez-Ruiz, M.R. Pazos, M. Garcia-Arencibia, O. Sagredo, and J.A. Ramos Role of CB2 receptors in neuroprotective effects of cannabinoids Mol. Cell. Endocrinol. 286 2008 S91 S96
12. J. Fernandez-Ruiz, J. Romero, G. Velasco, R.M. Tolon, J.A. Ramos, and M. Guzman Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28 2007 39 45
13. J. Fernandez-Ruiz, M. Moreno-Martet, C. Rodriguez-Cueto, C. Palomo-Garo, M. Gomez-Canas, S. Valdeolivas, C. Guaza, J. Romero, M. Guzman, R. Mechoulam, and J.A. Ramos Prospects for cannabinoid therapies in basal ganglia disorders Br. J. Pharmacol. 163 2011 1365 1378
14. F. Fezza, C. De Simone, D. Amadio, and M. Maccarrone Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system Subcell. Biochem. 49 2008 101 132
15. C.J. Fowler Transport of endocannabinoids across the plasma membrane and within the cell FEBS J. 280 2013 1895 1904
16. T.F. Freund, I. Katona, and D. Piomelli Role of endogenous cannabinoids in synaptic signaling Physiol. Rev. 83 2003 1017 1066
17. A. Giuffrida, L.H. Parsons, T.M. Kerr, F. Rodriguez de Fonseca, M. Navarro, and D. Piomelli Dopamine activation of endogenous cannabinoid signaling in dorsal striatum Nat. Neurosci. 2 1999 358 363
18. G. Gobbi, F.R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, M. Solinas, T. Cassano, M.G. Morgese, G. Debonnel, A. Duranti, A. Tontini, G. Tarzia, M. Mor, V. Trezza, S.R. Goldberg, V. Cuomo, and D. Piomelli Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proc. Natl. Acad. Sci. U. S. A. 102 2005 18620 18625
19. J. Goncalves, S. Baptista, T. Martins, N. Milhazes, F. Borges, C.F. Ribeiro, J.O. Malva, and A.P. Silva Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin Eur. J. Neurosci. 31 2010 315 326
20. J. Haller, B. Varga, C. Ledent, and T.F. Freund CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents Behav. Pharmacol. 15 2004 299 304
21. J. Haller, N. Bakos, M. Szirmay, C. Ledent, and T.F. Freund The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety Eur. J. Neurosci. 16 2002 1395 1398
22. T. Hayashi, H. Hirata, M. Asanuma, B. Ladenheim, L.I. Tsao, J.L. Cadet, and T.P. Su Delta opioid peptide [D-Ala2, D-Leu5]enkephalin causes a near complete blockade of the neuronal damage caused by a single high dose of methamphetamine: examining the role of p53 Synapse 39 2001 305 312
23. A.C. Howlett, L.C. Blume, and G.D. Dalton CB(1) cannabinoid receptors and their associated proteins Curr. Med. Chem. 17 2010 1382 1393
24. Z. Justinova, R.A. Mangieri, M. Bortolato, S.I. Chefer, A.G. Mukhin, J.R. Clapper, A.R. King, G.H. Redhi, S. Yasar, D. Piomelli, and S.R. Goldberg Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates Biol. Psychiatry 64 2008 930 937
25. S. Kathuria, S. Gaetani, D. Fegley, F. Valino, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. La Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery, V. Cuomo, and D. Piomelli Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 9 2003 76 81
26. S.G. Kinsey, S.T. O'Neal, J.Z. Long, B.F. Cravatt, and A.H. Lichtman Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay Pharmacol. Biochem. Behav. 98 2011 21 27
27. T. Kita, I. Miyazaki, M. Asanuma, M. Takeshima, and G.C. Wagner Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity Int. Rev. Neurobiol. 88 2009 43 64
28. I.N. Krasnova, and J.L. Cadet Methamphetamine toxicity and messengers of death Brain Res. Rev. 60 2009 379 407
29. K.C. Lan, A.C. Chang, S.H. Liu, I.K. Ho, and S.Y. Lin-Shiau Enhancing effects of morphine on methamphetamine-induced reinforcing behavior and its association with dopamine release and metabolism in mice J. Neurochem. 109 2009 382 392
30. I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, and J. Fernandez-Ruiz Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease Neurobiol. Dis. 19 2005 96 107
31. J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, J.E. Schlosburg, F.J. Pavon, A.M. Serrano, D.E. Selley, L.H. Parsons, A.H. Lichtman, and B.F. Cravatt Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects Nat. Chem. Biol. 5 2009 37 44
32. M. Maccarrone, E. Dainese, and S. Oddi Intracellular trafficking of anandamide: new concepts for signaling Trends Biochem. Sci. 35 2010 601 608
33. G. Marsicano, and B. Lutz Neuromodulatory functions of the endocannabinoid system J. Endocrinol. Investig. 29 2006 27 46
34. G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, A. Cannich, S.C. Azad, M.G. Cascio, S.O. Gutierrez, M. van der Stelt, M.L. Lopez-Rodriguez, E. Casanova, G. Schutz, W. Zieglgansberger, V. Di Marzo, C. Behl, and B. Lutz CB1 cannabinoid receptors and on-demand defense against excitotoxicity Science 302 2003 84 88
35. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
36. M.K. McKinney, and B.F. Cravatt Structure and function of fatty acid amide hydrolase Annu. Rev. Biochem. 74 2005 411 432
37. R. Mechoulam, and L.A. Parker The endocannabinoid system and the brain Annu. Rev. Psychol. 64 2013 21 47
38. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N.E. Kaminski, A.R. Schatz, A. Gopher, S. Almog, B.R. Martin, and D.R. Compton Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 50 1995 83 90
39. M. Melis, M. Pistis, S. Perra, A.L. Muntoni, G. Pillolla, and G.L. Gessa Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors J. Neurosci. 24 2004 53 62
40. M. Melis, G. Pillolla, T. Bisogno, A. Minassi, S. Petrosino, S. Perra, A.L. Muntoni, B. Lutz, G.L. Gessa, G. Marsicano, V. Di Marzo, and M. Pistis Protective activation of the endocannabinoid system during ischemia in dopamine neurons Neurobiol. Dis. 24 2006 15 27
41. R. Moldzio, T. Pacher, C. Krewenka, B. Kranner, J. Novak, J.C. Duvigneau, and W.D. Rausch Effects of cannabinoids Delta(9)-tetrahydrocannabinol, Delta(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures Phytomedicine 19 2012 819 824
42. M. Mor, S. Rivara, A. Lodola, P.V. Plazzi, G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, S. Kathuria, and D. Piomelli Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies J. Med. Chem. 47 2004 4998 5008
43. M. Morales, and A. Bonci Getting to the core of addiction: Hooking CB2 receptor into drug abuse? Nat. Med. 18 2012 504 505
44. F.A. Moreira, N. Kaiser, K. Monory, and B. Lutz Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors Neuropharmacology 54 2008 141 150
45. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
46. A. Nakajima, K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, T. Mamiya, J. He, A. Nitta, M. Mizuno, M.H. Tran, A. Seto, M. Yoshimura, K. Kitaichi, T. Hasegawa, K. Saito, Y. Yamada, M. Seishima, K. Sekikawa, H.C. Kim, and T. Nabeshima Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity J. Neurosci. 24 2004 2212 2225
47. S. Oddi, F. Fezza, N. Pasquariello, A. D'Agostino, G. Catanzaro, C. De Simone, C. Rapino, A. Finazzi-Agro, and M. Maccarrone Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins Chem. Biol. 16 2009 624 632
48. E.S. Onaivi, H. Ishiguro, S. Gu, and Q.R. Liu CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity J. Psychopharmacol. 26 2012 92 103
49. F.C. Pereira, S.Z. Imam, B. Gough, G.D. Newport, C.F. Ribeiro, W. Slikker Jr., T.R. Macedo, and S.F. Ali Acute changes in dopamine release and turnover in rat caudate nucleus following a single dose of methamphetamine J. Neural Transm. 109 2002 1151 1158
50. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P. Alexander, V. Di Marzo, M.R. Elphick, P.J. Greasley, H.S. Hansen, G. Kunos, K. Mackie, R. Mechoulam, and R.A. Ross International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2) Pharmacol. Rev. 62 2010 588 631
51. D. Piomelli The molecular logic of endocannabinoid signalling Nat. Rev. Neurosci. 4 2003 873 884
52. D.A. Price, A.A. Martinez, A. Seillier, W. Koek, Y. Acosta, E. Fernandez, R. Strong, B. Lutz, G. Marsicano, J.L. Roberts, and A. Giuffrida WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease Eur. J. Neurosci. 29 2009 2177 2186
53. M. Pucci, N. Pasquariello, N. Battista, M. Di Tommaso, C. Rapino, F. Fezza, M. Zuccolo, R. Jourdain, A. Finazzi Agro, L. Breton, and M. Maccarrone Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor J. Biol. Chem. 287 2012 15466 15478
54. M.S. Quinton, and B.K. Yamamoto Causes and consequences of methamphetamine and MDMA toxicity AAPS J. 8 2006 E337 E347
55. K.H. Raitio, O.M. Salo, T. Nevalainen, A. Poso, and T. Jarvinen Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands Curr. Med. Chem. 12 2005 1217 1237
56. Y. Sekine, Y. Ouchi, G. Sugihara, N. Takei, E. Yoshikawa, K. Nakamura, Y. Iwata, K.J. Tsuchiya, S. Suda, K. Suzuki, M. Kawai, K. Takebayashi, S. Yamamoto, H. Matsuzaki, T. Ueki, N. Mori, M.S. Gold, and J.L. Cadet Methamphetamine causes microglial activation in the brains of human abusers J. Neurosci. 28 2008 5756 5761
57. S.L. Simon, C. Domier, J. Carnell, P. Brethen, R. Rawson, and W. Ling Cognitive impairment in individuals currently using methamphetamine Am. J. Addict. 9 2000 222 231
58. M. Solinas, S.R. Goldberg, and D. Piomelli The endocannabinoid system in brain reward processes Br. J. Pharmacol. 154 2008 369 383
59. M. Solinas, Z. Justinova, S.R. Goldberg, and G. Tanda Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats J. Neurochem. 98 2006 408 419
60. M. Solinas, L.V. Panlilio, K. Antoniou, L.A. Pappas, and S.R. Goldberg The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats J. Pharmacol. Exp. Ther. 306 2003 93 102
61. D. Sulzer, T.K. Chen, Y.Y. Lau, H. Kristensen, S. Rayport, and A. Ewing Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport J. Neurosci. 15 1995 4102 4108
62. J.J. Sumislawski, T.S. Ramikie, and S. Patel Reversible gating of endocannabinoid plasticity in the amygdala by chronic stress: a potential role for monoacylglycerol lipase inhibition in the prevention of stress-induced behavioral adaptation Neuropsychopharmacology 36 2011 2750 2761
63. N. Thiriet, X. Deng, M. Solinas, B. Ladenheim, W. Curtis, S.R. Goldberg, R.D. Palmiter, and J.L. Cadet Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum J. Neurosci. 25 2005 5273 5279
64. N. Thiriet, B. Gennequin, V. Lardeux, C. Chauvet, M. Decressac, T. Janet, M. Jaber, and M. Solinas Environmental enrichment does not reduce the rewarding and neurotoxic effects of methamphetamine Neurotox. Res. 19 2011 172 182
65. E. Torres, M.D. Gutierrez-Lopez, A. Mayado, A. Rubio, E. O'Shea, and M.I. Colado Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity J. Neuroinflammation 8 2011 53
66. E. Torres, M.D. Gutierrez-Lopez, E. Borcel, I. Peraile, A. Mayado, E. O'Shea, and M.I. Colado Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain J. Neurochem. 113 2010 67 78
67. C. Tourino, A. Zimmer, and O. Valverde THC prevents MDMA neurotoxicity in mice PLoS One 5 2010 e9143
68. M. van der Stelt, and V. Di Marzo Cannabinoid receptors and their role in neuroprotection Neuromolecular Med. 7 2005 37 50
69. M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis, D. Piomelli, J.S. Davison, L.J. Marnett, V. Di Marzo, Q.J. Pittman, K.D. Patel, and K.A. Sharkey Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 310 2005 329 332
70. M.T. Viscomi, S. Oddi, L. Latini, N. Pasquariello, F. Florenzano, G. Bernardi, M. Molinari, and M. Maccarrone Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway J. Neurosci. 29 2009 4564 4570
71. N.D. Volkow, L. Chang, G.J. Wang, J.S. Fowler, M. Leonido-Yee, D. Franceschi, M.J. Sedler, S.J. Gatley, R. Hitzemann, Y.S. Ding, J. Logan, C. Wong, and E.N. Miller Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers Am. J. Psychiatry 158 2001 377 382
72. L. Walter, and N. Stella Cannabinoids and neuroinflammation Br. J. Pharmacol. 141 2004 775 785
73. L. Walter, A. Franklin, A. Witting, C. Wade, Y. Xie, G. Kunos, K. Mackie, and N. Stella Nonpsychotropic cannabinoid receptors regulate microglial cell migration J. Neurosci. 23 2003 1398 1405
74. J.M. Wilson, K.S. Kalasinsky, A.I. Levey, C. Bergeron, G. Reiber, R.M. Anthony, G.A. Schmunk, K. Shannak, J.W. Haycock, and S.J. Kish Striatal dopamine nerve terminal markers in human, chronic methamphetamine users Nat. Med. 2 1996 699 703
75. R.I. Wilson, and R.A. Nicoll Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses Nature 410 2001 588 592
76. B.K. Yamamoto, and W. Zhu The effects of methamphetamine on the production of free radicals and oxidative stress J. Pharmacol. Exp. Ther. 287 1998 107 114
77. J.P. Zhu, W. Xu, and J.A. Angulo Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice Brain Res. 1049 2005 171 181
78. J.P. Zhu, W. Xu, N. Angulo, and J.A. Angulo Methamphetamine-induced striatal apoptosis in the mouse brain: comparison of a binge to an acute bolus drug administration Neurotoxicology 27 2006 131 136